Novacyt (LON:NCYT) Stock Price Up 8.2% – Still a Buy?

Novacyt S.A. (LON:NCYT)’s share price rose 8.2% on Friday . The stock traded as high as GBX 48.19 and last traded at GBX 47.40. Approximately 467,827 shares were traded during mid-day trading, an increase of 145% from the average daily volume of 191,231 shares. The stock had previously closed at GBX 43.80.

Novacyt Price Performance

The company has a current ratio of 4.74, a quick ratio of 4.46 and a debt-to-equity ratio of 44.73. The company’s fifty day moving average is GBX 35.03 and its two-hundred day moving average is GBX 36.11. The stock has a market cap of £34.42 million, a price-to-earnings ratio of -1.10 and a beta of 0.97.

Novacyt (LON:NCYT) last posted its earnings results on Thursday, April 30th. The company reported GBX (33) earnings per share for the quarter. Novacyt had a negative net margin of 135.96% and a negative return on equity of 111.34%. The company had revenue of GBX 2,003 million during the quarter.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.